On November 19, 2024, Karin Eastham, a Director at Veracyte Inc (VCYT, Financial), sold 14,731 shares of the company, as reported in a SEC Filing. Following this transaction, the insider now holds 18,497 shares of Veracyte Inc.
Veracyte Inc is a genomic diagnostics company that provides genomic tests to improve diagnostic accuracy and reduce unnecessary surgeries and other invasive procedures. The company focuses on areas such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis.
Over the past year, Karin Eastham has sold a total of 28,601 shares and has not purchased any shares. The insider transaction history for Veracyte Inc indicates that there have been no insider buys and 18 insider sells over the same period.
On the day of the recent sale, shares of Veracyte Inc were trading at $38.34, giving the stock a market cap of $3.017 billion. The stock's GF Value is estimated at $32.20, resulting in a price-to-GF-Value ratio of 1.19, indicating that the stock is modestly overvalued.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also considers a GuruFocus adjustment factor based on the company’s past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
